RESUMEN

Herpes simplex encephalitis (HSE) is characterized by severe focal brain inflammation leading to substantial loss of nervous tissue. The authors established a model of Herpes simplex virus type 1 (HSV)-1-induced acute encephalitis in the rat by injecting into the whiskers' area a virus strain isolated from a fatal human HSE case. The model might resemble natural propagation of HSV-1 in humans; spreading from the mouth and lips via the trigeminal nerve to trigeminal ganglia and subsequently entering the central nervous system (CNS). HSV-1 infected Dark Agouti (DA) rats developed a well-synchronized disease and died 5 days after inoculation. HSV-1 detection by quantitative polymerase chain reaction (qPCR), virus isolation and immunohistochemistry, magnetic resonance imaging, and histopathological examination verified dramatic encephalitis mainly in the brainstem, but also in the olfactory bulb and other segments of the brain of diseased rats. In contrast, Piebald Virol Glaxo (PVG) rats were completely resistant to disease, displaying a more rapid clearance of peripheral infection and no evidence of virus entering into neither the trigeminal ganglia nor the CNS. These results suggest a regulation of susceptibility to HSV-1-induced encephalitis at the level of peripheral infection and subsequent neuronal uptake/transport of the virus. This provides a basis for future positioning of genetic polymorphisms regulating HSE and for dissection of important pathogenetic mechanisms of this severe human disease.

Asunto(s)

Encefalitis por Herpes Simple/inmunología , Encefalitis por Herpes Simple/microbiología , Herpesvirus Humano 1/aislamiento & purificación , Animales , Tronco Encefálico/metabolismo , ADN Viral/análisis , Modelos Animales de Enfermedad , Susceptibilidad a Enfermedades , Encefalitis por Herpes Simple/genética , Encefalitis por Herpes Simple/patología , Humanos , Ratas , Ganglio del Trigémino/microbiología

RESUMEN

In this study, we investigated regulatory mechanisms and plasticity of the nicotinic acetylcholine receptors (nAChRs) in the brain and adrenal glands of two transgenic mice models over-expressing human beta-amyloid precursor protein (APP(SWE)Tg) and human AChE enzyme (hAChE-Tg), respectively. All animals were studied at 3 months of age. Binding studies showed higher (125)I-alpha-bungarotoxin (alpha7 nAChRs) and (3)H-epibatidine (alpha3 and alpha4 nAChRs) binding in the brain cortex and adrenal glands of hAChE-Tg mice compared to control mice. The APP(SWE)Tg mice showed a significantly lower relative level for the alpha4 mRNA in the brain cortex as well as a lower level of alpha3 mRNA, and higher level of alpha7 mRNA in the adrenal glands compared to control mice. A higher relative mRNA level of alpha3 and alpha4 nAChRs was observed in the brain as well as of alpha3 and alpha7 nAChRs in the adrenal glands of hAChE-Tg mice compared to control mice. Different nicotinic receptor plasticity is revealed in the brain cortex and adrenal glands in two transgenic mice models with different underlying pathophysiological mechanisms. Deposition of beta-amyloid (Abeta) may impair neurotransmitter activity in brain as well as in the adrenal gland.

Asunto(s)

Acetilcolinesterasa/metabolismo , Glándulas Suprarrenales/metabolismo , Enfermedad de Alzheimer/metabolismo , Precursor de Proteína beta-Amiloide/metabolismo , Encéfalo/metabolismo , Receptores Nicotínicos/metabolismo , Acetilcolinesterasa/genética , Precursor de Proteína beta-Amiloide/genética , Animales , Modelos Animales de Enfermedad , Femenino , Humanos , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Receptores Nicotínicos/clasificación , Proteínas Recombinantes/metabolismo , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Distribución Tisular

RESUMEN

Overexpression of acetylcholinesterase (AChE) in mice causes cholinergic deficits with memory impairment. In this study, AChE overexpressing (hAChE-Tg) and control (FVB/N) mice were treated with the AChE inhibitor (AChEI) galantamine (4 mg/kg/day) for 10 days. The concentration of galantamine in plasma was 75-80 ng/ml. The inhibition of AChE was 20% in red blood cells (RBC) and 30% in brain cortical tissue. A significant increase in [(3)H]cytisine (alpha4 nicotinic receptor) binding was measured in the CA1 and CA3 area of the hippocampus of FVB/N mice following galantamine treatment. Similarly, a significant increase in [(125)I]alphabungarotoxin (alpha7 nicotinic receptor) binding was found in the frontal cortex, retrosplenial gr. cortex, motor cortex and thalamus in galantamine treated FVB/N compared to saline treated mice. No significant changes in nicotinic receptor binding sites were observed in galantamine treated hAChE-Tg mice. Significant decreases in the muscarinic receptors measured by [(3)H]AF-DX-384 (M2 muscarinic receptor) and [(3)H]pirenzepine (M1 muscarinic receptor) were observed in several brain regions of galantamine treated FVB/N and hAChE-Tg mice. This study shows regional and receptor subtype specific changes in the nicotinic receptor subtypes compared to the muscarinic receptors following galantamine treatment in FVB/N and hAChE-Tg mice.

Asunto(s)

Acetilcolinesterasa/biosíntesis , Galantamina/administración & dosificación , Neuronas/efectos de los fármacos , Receptores Muscarínicos/biosíntesis , Receptores Nicotínicos/biosíntesis , Acetilcolinesterasa/genética , Animales , Encéfalo/efectos de los fármacos , Encéfalo/enzimología , Inhibidores de la Colinesterasa/farmacología , Femenino , Regulación Enzimológica de la Expresión Génica/fisiología , Humanos , Masculino , Ratones , Ratones Transgénicos , Neuronas/enzimología , Unión Proteica/efectos de los fármacos , Unión Proteica/fisiología , Subunidades de Proteína/biosíntesis

RESUMEN

The effect of the nicotinic acetylcholine receptors (nAChRs) agonist (+/-)epibatidine on the modulation of dopamine (DA) release was investigated by microdialysis in vivo in the frontal cortex and the nucleus accumbens of naive and chronic nicotine-treated awake rats. (+/-)Epibatidine (2.5 microg/kg, s.c.), contrary to (-)nicotine (0.5 mg/kg, s.c.), decreased the extracellular concentrations of DA in the brain of naive rats. Subchronic nicotine treatment (0.45 mg/kg, s.c., twice daily for 7 days) attenuated the (+/-)epibatidine induced decrease in the DA level. The extracellular concentrations of the DA metabolites 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) were elevated by (+/-)epibatidine administration in both naïve and subchronic treated rats. The findings suggest that the decrease in DA extracellular concentrations induced by the high affinity nAChRs agonist (+/-)epibatidine might be due to inactivation of nAChRs, which can be overcome by subchronic treatment with nicotine. Different mechanisms in modulation of DA release appears to be involved in the rat brain by (+/-)epibatidine compare to (-)nicotine.

Asunto(s)

Compuestos Bicíclicos Heterocíclicos con Puentes/farmacología , Dopamina/metabolismo , Lóbulo Frontal/efectos de los fármacos , Lóbulo Frontal/metabolismo , Nicotina/administración & dosificación , Agonistas Nicotínicos/farmacología , Núcleo Accumbens/efectos de los fármacos , Núcleo Accumbens/metabolismo , Piridinas/farmacología , Animales , Masculino , Ratas , Ratas Sprague-Dawley

RESUMEN

Ten days treatment with nicotine reduced insoluble amyloid A beta 1-40 and Alpha beta 1-42 peptides by 80% in the cortex of 9-month-old APPsw mice, which is more than that observed in 14.5-month-old mice following nicotine treatment for 5.5 months. A reduction in A beta associated with cerebral vessels was observed in addition to that deposited as parenchymal plaques after 5.5 months treatment. The diminution in A beta peptides observed was not accompanied by changes in brain alpha, beta or gamma secretase-like activities, NGF or BDNF protein expression measured in brain homogenates. A significant increase in sAPP was observed after nicotine treatment of SH-SY5Yneuroblastoma cells that could be blocked by the nicotinic antagonist mecamylamine. Attenuation of elevated [(125)I]-alpha bungarotoxin binding (alpha 7) in APPsw mice was observed after 5.5 months nicotine treatment. Both these observations suggest that the reduction in insoluble A beta by nicotine might be in part mediated via the alpha 7 nicotinic receptor. Further studies are required to identify potential mechanisms of the nicotine's amyloid-reducing effect.

Asunto(s)

Péptidos beta-Amiloides/metabolismo , Vasos Sanguíneos/efectos de los fármacos , Encéfalo/efectos de los fármacos , Arterias Cerebrales/efectos de los fármacos , Nicotina/administración & dosificación , Factores de Edad , Secretasas de la Proteína Precursora del Amiloide , Péptidos beta-Amiloides/análisis , Péptidos beta-Amiloides/sangre , Precursor de Proteína beta-Amiloide/genética , Precursor de Proteína beta-Amiloide/metabolismo , Animales , Ácido Aspártico Endopeptidasas , Western Blotting/métodos , Encéfalo/metabolismo , Química Encefálica , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Bungarotoxinas/farmacocinética , Línea Celular Tumoral , Arterias Cerebrales/metabolismo , Esquema de Medicación , Embrión de Mamíferos , Endopeptidasas/metabolismo , Transportador de Glucosa de Tipo 1 , Humanos , Inmunohistoquímica/métodos , Isótopos de Yodo/farmacocinética , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Proteínas de Transporte de Monosacáridos/metabolismo , Factor de Crecimiento Nervioso/metabolismo , Neuroblastoma , Nicotina/farmacología , Fragmentos de Péptidos/análisis

RESUMEN

Subtypes of nicotinic (alpha4 and alpha7) as well as muscarinic (M1 and M2) receptor binding sites were quantified in the brain of transgenic mice overexpressing human acetylcholinesterase (AChE) at different ages using selective radioligands. A significant increase in [(3)H]cytisine (alpha4) binding was found in the cortex and striatum of AChE transgenic (hAChE-Tg) mice from 3 days to 12 months of age in comparison to non-transgenic mice. In addition a significant increase in [(3)H]AF-DX-384 (M2) binding was found in the striatum of hAChE-Tg mice at 3 months of age compared to controls. No major alteration was observed in the [(125)I]alpha-bungarotoxin (alpha7) or the [(3)H]pirenzepine (M1) binding sites. The persistent increase in alpha4 and M2 receptor binding sites in hAChE-Tg mice suggests that these receptor subtypes may play an important role in compensatory mechanisms facilitating the impaired cholinergic neurotransmission in hAChE-Tg.

Asunto(s)

Acetilcolinesterasa/biosíntesis , Neuronas/metabolismo , Receptores Muscarínicos/metabolismo , Receptores Nicotínicos/metabolismo , Acetilcolinesterasa/genética , Factores de Edad , Animales , Encéfalo/metabolismo , Humanos , Ratones , Ratones Transgénicos , Receptor Muscarínico M2

RESUMEN

The nicotinic (nAChRs) and muscarinic (mAChRs) acetylcholine receptors and acetylcholinesterase (AChE) activity were studied in the brains of APP(SWE) transgenic mice (Tg+) and age-matched nontransgenic controls (Tg-) that were between 4 and 19 months of age. A significant increase in the binding of 125I-labeled alpha-bungarotoxin (alpha7 nAChRs) was observed in most brain regions analyzed in 4-month-old Tg+ mice, preceding learning and memory impairments and amyloid-beta (Abeta) pathology. The enhanced alpha7 receptor binding was still detectable at 17-19 months of age. Increase in [3H]cytisine binding (alpha4beta2 nAChRs) was measured at 17-19 months of age in Tg+ mice, at the same age when the animals showed heavy Abeta pathology. No significant changes in [3H]pirenzepine (M1 mAChRs) or [3H]AFDX 384 (M2 mAChRs) binding sites were found at any age studied. The upregulation of the nAChRs probably reflects compensatory mechanisms in response to Abeta burden in the brains of Tg+ mice.

Asunto(s)

Enfermedad de Alzheimer/genética , Péptidos beta-Amiloides/biosíntesis , Precursor de Proteína beta-Amiloide/genética , Encéfalo/metabolismo , Neuronas/metabolismo , Receptores Nicotínicos/metabolismo , Regulación hacia Arriba/genética , Acetilcolinesterasa/metabolismo , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/fisiopatología , Péptidos beta-Amiloides/genética , Péptidos beta-Amiloides/metabolismo , Animales , Sitios de Unión/genética , Encéfalo/patología , Encéfalo/fisiopatología , Modelos Animales de Enfermedad , Femenino , Discapacidades para el Aprendizaje/genética , Discapacidades para el Aprendizaje/metabolismo , Discapacidades para el Aprendizaje/fisiopatología , Masculino , Aprendizaje por Laberinto/fisiología , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Neuronas/patología , Fragmentos de Péptidos/metabolismo , Placa Amiloide/genética , Placa Amiloide/metabolismo , Placa Amiloide/patología , ARN Mensajero/metabolismo , Ensayo de Unión Radioligante , Receptores Muscarínicos/metabolismo , Receptores Nicotínicos/genética , Receptor Nicotínico de Acetilcolina alfa 7

RESUMEN

Alzheimer's disease neuropathology is characterised by beta-amyloid plaques and neurofibrillary tangles. Inhibition of beta-amyloid accumulation may be essential for effective therapy in Alzheimer's disease. In this study we have treated transgenic mice carrying the Swedish mutation of human amyloid precursor protein [Tg(Hu.APP695.K670N-M671L)2576], which develop brain beta-amyloid deposits, with nicotine in drinking fluid (200 microg/mL) from 9-14.5 months of age (5.5 months). A significant reduction in amyloid beta peptide 1-42 positive plaques by more than 80% (p < 0.03) was observed in the brains of nicotine treated compared to sucrose treated transgenic mice. In addition, there was a selective reduction in extractable amyloid beta peptides in nicotine treated mice; cortical insoluble 1-40 and 1-42 peptide levels were lower by 48 and 60%, respectively (p < 0.005), whilst there was no significant change in soluble 1-40 or 1-42 levels. The expression of glial fibrillary acidic protein was not affected by nicotine treatment. These results indicate that nicotine may effectively reduce amyloid beta peptide aggregation in brain and that nicotinic drug treatment may be a novel protective therapy in Alzheimer's disease.

Asunto(s)

Enfermedad de Alzheimer/tratamiento farmacológico , Nicotina/administración & dosificación , Placa Amiloide/efectos de los fármacos , Administración Oral , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/análisis , Péptidos beta-Amiloides/biosíntesis , Animales , Astrocitos/metabolismo , Astrocitos/patología , Química Encefálica , Recuento de Células , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Corteza Cerebral/patología , Modelos Animales de Enfermedad , Progresión de la Enfermedad , Esquema de Medicación , Femenino , Proteína Ácida Fibrilar de la Glía/biosíntesis , Hipocampo/química , Humanos , Inmunohistoquímica , Masculino , Ratones , Ratones Transgénicos , Vías Olfatorias/química , Fragmentos de Péptidos/análisis , Fragmentos de Péptidos/biosíntesis , Placa Amiloide/metabolismo , Placa Amiloide/patología , Factores Sexuales , Resultado del Tratamiento

RESUMEN

Alzheimer's disease (AD) is a progressive neurodegenerative disorder, of which the pathogenesis is thought to involve increased beta-amyloid (Abeta) deposition and abnormal immunological responses. To elucidate the mechanisms involved in Abeta-mediated inflammation, we used immunocytochemistry and in situ hybridization to study the potential role of the cytokines interferon-gamma (IFN-gamma), interleukin (IL)-12 and IL-4 in transgenic mice APP(SWE) (Tg2576) that overexpress the human beta-amyloid precursor protein gene. Cytokine and cytokine mRNA expression was detected in brain sections from cortical regions at various postnatal ages ranging from 3 to 19 months. High levels of IFN-gamma and IL-12 mRNA expression, as well as their protein production, appeared early at 9 months and peaked at 17-19 months in Tg2576 mice. Significantly increased transcripts of IFN-gamma and IL-12 genes were found in the reactive microglia and astrocytes surrounding beta-amyloid deposits. In accordance with the kinetics of mRNA levels, the expression of IFN-gamma and IL-12 at the protein level was positively correlated with age and reached a maximum in 17-19-month-old mice. Both findings suggest a role for the pro-inflammatory cytokines IFN-gamma and IL-12 in early disease development and are consistent with microglial activation related to beta-amyloid formation. In contrast, transcription and production of IL-4 in brain sections was almost undetectable in transgenic mice up to post-natal ages of 17-19 months. These results suggest a major pro-inflammatory role for IL-12 and IFN-gamma in Tg2576 transgenic mice that may provide the association between beta-amyloid plaque formation and microglial and astrocyte activation in these animals. These observations call for further studies on the potential role of anti-inflammatory therapeutic strategies for AD.

Asunto(s)

Precursor de Proteína beta-Amiloide/genética , Corteza Cerebral/inmunología , Interferón gamma/genética , Interleucina-12/genética , Interleucina-4/genética , Factores de Edad , Animales , Corteza Cerebral/metabolismo , Regulación hacia Abajo/inmunología , Femenino , Expresión Génica/inmunología , Interferón gamma/inmunología , Interferón gamma/metabolismo , Interleucina-12/inmunología , Interleucina-12/metabolismo , Interleucina-4/inmunología , Interleucina-4/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , ARN Mensajero/análisis , Regulación hacia Arriba/inmunología